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A BS T R AC T
BACKGROUND

Hypophosphatasia results from mutations in the gene for the tissue-nonspecific isozyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates
extracellularly, leading to rickets or osteomalacia. Severely affected babies often die
from respiratory insufficiency due to progressive chest deformity or have persistent
bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted,
recombinant human TNSALP that prevents the manifestations of hypophosphatasia
in Tnsalp knockout mice.
METHODS

We enrolled infants and young children with life-threatening or debilitating perinatal
or infantile hypophosphatasia in a multinational, open-label study of treatment with
ENB-0040. The primary objective was the healing of rickets, as assessed by means of
radiographic scales. Motor and cognitive development, respiratory function, and safety
were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040.
RESULTS

Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year.
Healing of rickets at 6 months in 9 patients was accompanied by improvement in
developmental milestones and pulmonary function. Elevated plasma levels of the
TNSALP substrates inorganic pyrophosphate and pyridoxal 5′-phosphate diminished.
Increases in serum parathyroid hormone accompanied skeletal healing, often necessitating dietary calcium supplementation. There was no evidence of hypocalcemia,
ectopic calcification, or definite drug-related serious adverse events. Low titers of
anti–ENB-0040 antibodies developed in four patients, with no evident clinical, biochemical, or autoimmune abnormalities at 48 weeks of treatment.
CONCLUSIONS

ENB-0040, an enzyme-replacement therapy, was associated with improved findings on
skeletal radiographs and improved pulmonary and physical function in infants and
young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma
and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.)
n engl j med 366;10
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H

ypophosphatasia is the inborn error of metabolism that is characterized
by low serum alkaline-phosphatase activity from loss-of-function mutations, typically missense, within the gene for the tissue-nonspecific
isozyme of alkaline phosphatase (TNSALP).1 Natural substrates of TNSALP that accumulate in hypophosphatasia include inorganic pyrophosphate,2
an inhibitor of mineralization,3 and pyridoxal
5′-phosphate (PLP), the principal circulating form
of vitamin B6.4 High extracellular levels of inorganic pyrophosphate block hydroxyapatite crystal
growth3,5 and cause rickets or osteomalacia. Hypercalcemia and hyperphosphatemia can develop
in severely affected patients.1 The deranged vitamin B6 metabolism shows that TNSALP functions as a cell-surface enzyme6 and explains why
pyridoxine-responsive seizures may occur when
TNSALP deficiency is profound.7
The manifestations of hypophosphatasia range
from neonatal death with almost no skeletal mineralization to dental problems in adults without
any bone symptoms.1,5 Such differences in expression are explained partly by autosomal recessive
and autosomal dominant patterns of inheritance.1 From a clinical nosology based on the patient’s age when skeletal disease first develops,8
autosomal recessive inheritance explains all perinatal cases and nearly all infantile cases of hypophosphatasia.9-11 Perinatal hypophosphatasia is
characterized by extreme skeletal hypomineralization, and survival is rare.1,12 Infantile hypophosphatasia develops before 6 months of age with
rickets, failure to thrive, hypotonia, and myopathy and is often complicated by hypercalcemia,
nephrocalcinosis, epilepsy, and craniosynostosis.7,13-18 Deciduous teeth are lost because insufficient cementum links them to the periodontal
ligament.19 Although spontaneous improvement
sometimes occurs in infantile hypophosphatasia,20 substantial bone disease and weakness
often persist.1,5 Skeletal deterioration typically
results in death from respiratory insufficiency.14-17
Attempts to treat patients with infantile hypophosphatasia by administering intravenous infusions of plasma enriched in soluble alkaline phosphatase from patients with Paget’s disease14,15 or
alkaline phosphatase purified from human placentas21 have been unsuccessful, suggesting that
skeletal mineralization requires the presence of
TNSALP on osteoblasts, chondrocytes, and matrix
vesicles.5,22,23 There is no approved medical treatment for hypophosphatasia.
n engl j med 366;10

ENB-0040 (asfotase alfa; Enobia Pharma) is
an investigational, recombinant, fusion protein
comprising the TNSALP ectodomain, the constant region of the human IgG1 Fc domain, and
a terminal deca-aspartate motif for bone targeting.24 In Tnsalp knockout mice, which constitute
an animal model of infantile hypophosphatasia,25 treatment with daily subcutaneous injections of ENB-0040 at doses that result in serum
levels ranging from 650 to 1000 U per liter preserve the mineralization of bones and teeth.24,26,27
A phase 1 study involving adult patients with hypophosphatasia showed peak and trough ENB-0040
levels in this range after one intravenous dose of
3 mg per kilogram of body weight and weekly
subcutaneous doses of 2 mg per kilogram.28 We
conducted a clinical trial of treatment with ENB0040 for at least 1 year in infants and young
children with life-threatening hypophosphatasia.

ME THODS
STUDY DESIGN AND PATIENTS

In an open-label study, we evaluated the safety,
tolerability, bioavailability, pharmacokinetics,29
pharmacodynamics, and efficacy of treatment with
ENB-0040. Efficacy assessments included skeletal
changes, as evaluated by means of radiography, and
gross motor, fine motor, and cognitive development, as measured with the Bayley Scales of Infant
and Toddler Development, third edition (Bayley-III),
a norm-referenced instrument used to assess developmental functioning of children from 1 to 42
months of age and to identify children with developmental delay. Raw scores of successfully completed items are converted to scaled and composite
scores allowing comparison with children in a
standardized sample. Developmental age-equivalent scores in months allow raw-score comparisons with typically developing children.30 All patients were to receive ENB-0040 for 6 months and
then have the opportunity to enroll in an openlabel extension study.
Eligibility criteria were an age of 3 years or
less, symptoms of hypophosphatasia occurring
before the age of 6 months, hypophosphatasemia,
an elevated plasma PLP level, hypophosphatasiarelated skeletal disease as assessed radiographically, failure to thrive, rachitic chest deformity or
pyridoxine-responsive seizures, and nontraumatic
or poorly healing fractures, hypercalcemia, craniosynostosis, nephrocalcinosis, or respiratory compromise from hypophosphatasia. Patients were
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Form of hypophosphatasia

Perinatal

Infantile

Infantile

Infantile

Perinatal

7.5

6

33

18

36

Female

Female

Female

Female

Female

Age — mo
Sex

c.881A>C p.D294A c.407G>A p.Arg136His c.658G>A p.Gly220Arg c.1077C>G p.Ile359Met c.98C>T p.A33V
c.547G>A
c.1133A>T
c.659G>C
c.1133A>T
c.98C>T
p.D183H†
p.Asp378Val‡
p.Gly220Ala§
p.Asp378Val‡
p.A33V†

TNSALP genotype

Serum ALP (normal range)
— U/liter¶
Plasma PLP — × ULN

20 (117–352)

8 (<390)

33 (108–317)

58 (80–425)

19 (79–267)

10

5

4

>3

2

Severity of rickets‖

Severe

Severe

Extremely severe

Severe

Moderate

Respiratory status

CPAP

Progressive respiratory
deterioration

Tracheostomy and
ventilation

Tracheostomy and
ventilation

Supplemental oxygen
by nasal cannula

Failure to thrive

Yes

Yes

Yes

Yes

Yes

Nephrocalcinosis

Yes

Yes

Yes

Yes

No

Gross motor function —
age-equivalent in mo**

<1

<1

<1

7

Tube

Tube

Oral

Feeding

Tube

No data — too fragile
to test
Tube

*		 ALP denotes alkaline phosphatase, CPAP continuous positive airway pressure, PLP pyridoxal 5′-phosphate, TNSALP tissue-nonspecific isozyme of alkaline phosphatase, and ULN upper limit of the normal range.
†		 TNSALP mutation analysis was performed by Centre d’Etudes de Biologie Prénatale, Université de Versailles (Versailles, France).
‡		 TNSALP mutation analysis was performed by Connective Tissue Gene Tests (Allentown, PA).
§		 TNSALP mutation analysis was performed by Steven Mumm, Ph.D., of the Washington University School of Medicine (St. Louis).
¶		 The normal range is for the center where the patient was treated.
‖		 Extremely severe rickets was defined as the partial or complete absence of visible bones on radiographs, severe rickets as a near absence
of metaphyseal features with large radiolucent “tongues” and sclerosis, and moderate rickets as rachitic changes (metaphyseal flaring and
fraying, widening of physes, areas of subphyseal demineralization, and bowing).
** Gross motor function was assessed with the use of the Bayley Scales of Infant and Toddler Development, third edition (Bayley-III), a
norm-referenced instrument used to assess developmental functioning of children from 1 to 42 months of age and to identify children
with developmental delay. Raw scores of successfully completed items are converted to scaled and composite scores allowing comparison
with children in a standardized sample. Developmental age-equivalent scores in months allow raw-score comparisons with typically developing children.30

excluded if they had a major coexisting disease,
a treatable form of rickets, previous exposure to
bisphosphonates, hypocalcemia or hypophosphatemia, or a serum 25-hydroxyvitamin D level of
less than 20 ng per milliliter (50 nM) or if they
had received another experimental treatment for
hypophosphatasia (e.g., bone marrow transplantation).16,17
STUDY OVERSIGHT

statistical analyses were performed by Statistics
Collaborative. Other organizations involved in the
management and analysis of study data are listed
in the Methods section in the Supplementary Appendix (available with the full text of this article
at NEJM.org). All the authors evaluated the study
findings, made the decision to submit the manuscript for publication, and vouch for the completeness and accuracy of the reported data and the
fidelity of the study to the protocol. The first author
wrote the first draft of the manuscript, and the
other authors aided in its revision. The study protocol, including the statistical analysis plan, is available at NEJM.org.

The study design was developed through a collaboration between the sponsor, Enobia Pharma, and
the authors. The protocol was approved by the
local institutional review boards, and written informed consent was obtained from the patients’
parents. Safety and efficacy were monitored quar- STUDY TREATMENT
terly and on an ad hoc basis by an independent Patients received ENB-0040 (at a concentration of
data and safety monitoring board. The primary 40 mg per milliliter) as a single intravenous infu906
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Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

Patient 11

Perinatal

Perinatal

Infantile

Infantile

Perinatal

Infantile

0.6

1

30

6

2

4

Male

Female

Male
c.119C>T p.Ala40Val
c.1231A>G
p.Thr411Ala‡

Male
c.215T>C p.Ile72Thr
c.881A>C
p.Asp294Ala‡

21 (73–266)

20 (73–266)

c.212G>A p.Arg71His c.212G>A p.R71H
c.571G>A
c.571G>A
p.Gly191Lys†
p.E191K†
42 (76–308)

Female
c.920C>T p.P307L
c.1171C>T
p.R391C‡

23 (59–425)

6 (32–91)

Male
c.350A>G p.Tyr117Cys
c.1001G>A
p.Gly334Asp‡
93 (143–320)

17

8

18

14

Receiving pyridoxine

3

Extremely severe

Severe

Moderate

Severe

Severe

Severe

Endotracheal intuba- Progressive respiratory
tion and ventilation
deterioration

Ambient air

Progressive respiratory Progressive respiratory Progressive respiratory
deterioration
deterioration
deterioration

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Kidney stones

No

Yes

Yes

Yes

<1

9

<1

1

<1

Tube

Oral

Tube

Oral

Oral

No data — too fragile
to test
Tube

sion at a dose of 2 mg per kilogram, followed by
subcutaneous injections three times per week at a
dose of 1 mg per kilogram. The subcutaneous dose
could be increased up to 3 mg per kilogram if there
was worsening failure to thrive, deteriorating pulmonary function, or no radiographic evidence of
skeletal improvement.
STATISTICAL ANALYSIS

The primary efficacy end point was a change in
the skeletal manifestations of hypophosphatasia,
including rickets, as assessed on radiography. Two
methods of assessment were used. First, three radiologists rated changes from baseline to week
48 using a 7-point scale (radiographic global impression of change [RGI-C]), which is based on
ratings of the characteristics of severe hypophosphatasia (including irregularity of the provisional
zone of calcification; physeal widening; metaphyseal flaring, fraying, radiolucencies, and patchy osteosclerosis; altered ratio of mid-diaphyseal cortexto-bone thickness; gracile bones; absence of some
or all bones; and recent fractures). A reduction of
3 points represented severe worsening, and an increase of 3 points indicated complete healing of the
skeletal disease. For each patient, the mean score
among the radiologists was used for analysis, with
a response to treatment defined as a mean increase
of 2 or more points (i.e., substantial healing).

n engl j med 366;10

The proportion of patients with a response, with
the 95% exact confidence interval, was calculated
at weeks 24 and 48.31 Two-sided Wilcoxon signedrank tests32 were used to determine whether the
median scores differed from 0 (i.e., no change).
Second, a single reader rated the growth-plate
abnormalities at the wrists and knees, using a
10-point rickets-severity scale (RSS),33 with higher
scores representing more severe rickets. All radiographs were rated with masking of sequence and
patient identifiers. Changes from baseline were
calculated at weeks 24 and 48, with the use of
Wilcoxon signed-rank tests to determine whether
median changes differed from 0 (see the Supplementary Appendix).
Additional efficacy studies included evaluations
of respiratory status and motor and cognitive function. Bone biopsy and densitometry were precluded
by the small size of the patients and their precarious clinical status.

R E SULT S
CHARACTERISTICS OF THE PATIENTS

A total of 11 patients, 7 girls and 4 boys, were enrolled between October 2008 and December 2009;
they ranged in age at baseline from 2 weeks to
3 years (Table 1). Five patients had perinatal hypophosphatasia, and six had infantile hypophos-
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B

Week 24

C

Week 48

D

Baseline

E

Week 24

F

Week 48
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infants received calcium-restricted formulas (with
the use of feeding tubes) for hypercalcemia, and
vitamin D supplementation, if it was being administered, was continued. All had hypophosphatasemia. Levels of plasma PLP were 2 to 18 times the
upper limit of the normal range in 10 patients,
with a higher level in the 1 patient who received
pyridoxine for vitamin B6–responsive seizures.
One patient was homozygous for a TNSALP missense mutation. The others were compound heterozygotes of 18 additional TNSALP missense mutations (Table 1). The case summaries, laboratory
findings, and radiographic changes are provided
in the Supplementary Appendix.
Treatment Findings

Consent for treatment was withdrawn for 1 of the
11 patients because of irritability, oxygen desaturation, rigors, and low-grade fever during receipt
of the intravenous dose. The other 10 patients completed 6 months of treatment and entered the extension study. One patient died from sepsis after
7.5 months of therapy. Nine patients are currently participating in the extension study, with an
average treatment duration of 18 months (range,
12 to 26) (see the Supplementary Appendix).
Immediately after the intravenous infusion, the
serum ENB-0040 level was as high as 14,200 U per
liter (normal range for TNSALP, approximately
100 to 400). After the patients received the subcutaneous dose of 1 mg per kilogram three times per
week, trough activity averaged 580 U per liter, and
with higher doses (i.e., subcutaneous injections of
up to 3 mg per kilogram three times per week),
values in or near the anticipated range of efficacy
were observed in all patients (see the Results
section in the Supplementary Appendix).24,26 The
weight-normalized model and the allometric (body
size) model29 fit the data similarly. However, the
allometric model provided the better fit for the
data, showing a bioavailability of ENB-0040 of
72% and an estimated half-life of approximately
5 days.

Figure 1. Radiographic Findings at Baseline and at Weeks 24 and 48
in Patient 2.
A radiograph obtained at baseline shows that the right radius and ulna metaphyses are flared and contain only focal, irregular calcification (Panel A). At
week 24, these metaphyses are mineralized, with distinct provisional zones
of calcification, and the metacarpals have wider widths and better-defined
cortexes and no longer have lytic areas at their bases (Panel B). At week 48,
the radius and ulna have better modeling (Panel C). The striking rickets involving the left lower limb in the baseline radiograph (Panel D) shows
marked improvement at week 24 but with a modeling defect featuring an
expanded distal femur (Panel E), which is improved at week 48 (Panel F).

PRIMARY END POINT

phatasia. All had symptoms before the age of
6 months, including failure to thrive, fractures,
and substantial motor delay or regression. Patients
with erupted teeth had lost dentition. All but two
patients had nephrocalcinosis or renal stones. The
908

n engl j med 366;10

Baseline radiographs in all patients showed hypophosphatasia-associated skeletal disease. Skeletal
healing became apparent as early as week 3 in Patient 2 and was striking at week 24 (Fig. 1 and 2)
in all patients except Patient 3, who had no visible
bone at baseline. No skeletal deterioration was observed, except in Patient 4, whose consent for treat-
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ment was withdrawn during the intravenous infusion and who subsequently had marked skeletal
demineralization (Fig. 3). Improvements in skeletal quality included diffusely increased mineral
content, corrected or improved endochondral and
membranous bone formation, fracture mending,
reduced deformity, resolution of radiolucencies and
sclerosis, and extensive modeling and remodeling.
RGI-C scores improved from baseline to week
24 and from baseline to week 48, with 9 of 10 patients (90%; 95% confidence interval [CI], 55 to
100) and 8 of 9 patients (89%; 95% CI, 52 to 100),
respectively, meeting the criterion for a treatment
response (see the Results section in the Supplementary Appendix). The patient who died from
sepsis was judged to have had a response at 24
weeks. The median RGI-C score was increased by
2.0 points at week 24 and by 2.3 points at week
48 (P = 0.004 for both comparisons), indicating
substantial and continued healing of rickets. Nearly all patients with a response had improvement in
physeal widening, metaphyseal flaring, irregularity of the provisional zone of calcification, and
metaphyseal radiolucencies. The patient with no
visible bone at baseline did not have an initial response to treatment but did have some remineralization at 48 weeks. The RSS score33 also improved
significantly. With the exclusion of the patient who
had no visible bone, the median RSS score at baseline was 9.5. At weeks 24 and 48, the median score
was reduced by 3.5 points (in 9 patients, P = 0.004)
and by 8.8 points (in 8 patients, P = 0.008), respectively (see the Supplementary Appendix).
SECONDARY END POINTS

At baseline, all but 1 patient had gracile or nonvisible ribs on radiographs, accompanied by respiratory compromise ranging from progressive insufficiency to frank ventilatory failure requiring full
mechanical ventilation (Table 1 and Video 1). Respiratory function tended to decline initially during
ENB-0040 therapy in the infants who were not receiving ventilatory support but then improved in all
patients, along with better mineralization of the rib
cage (Fig. 2), which was evident as early as week
12. At week 48, 6 of the 9 patients were breathing
ambient air without ventilatory support (as compared with 1 of 11 at baseline), 1 was receiving
supplemental oxygen through a nasal cannula,
1 was receiving mechanical ventilation only at
night, and 1 remained on full mechanical ventilation (see the Supplementary Appendix).
n engl j med 366;10

A

Baseline

B

Week 24

C

Baseline

D

Week 24

Figure 2. Radiographic Findings at Baseline and at Week 24 in Patient 6.
The baseline radiograph shows extreme hypomineralization of the left hand
(Panel A). Substantial mineralization is apparent at week 24 (Panel B). As
compared with the findings in the chest at baseline (Panel C), remineralization of all ossified structures of the chest (including ribs, clavicles, spine,
and scapulae) can be seen at week 24 (Panel D).

Performance on the Bayley-III instrument30 was
assessed at baseline in all but two patients (whose
medical condition was too fragile) and at weeks
24 and 48. At baseline, all the patients had gross
motor delays. None could bear weight through the
legs owing to skeletal abnormalities and muscle
weakness, including the four patients who were
18 months of age or older (Video 2). Improvements
in age-equivalent scores for gross motor, fine motor, and cognitive development were noted in seven
of the eight patients with complete evaluations. Of
the nine patients who were treated for 48 weeks,
all but two were bearing weight through the legs;
four were walking or taking early steps, one was
standing, two were crawling, and one was sitting
(Videos 3, 4, and 5). Patient 3, who at baseline had
no radiographically visible bone, had a tracheostomy, and had no spontaneous movement, moved
all limbs against gravity at 48 weeks.
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tory distress, craniosynostosis, and conductive
hearing loss) were considered by the investigators to be possibly related to the study treatment.
ENB-0040 did not appear to have an effect on
craniosynostosis, a progressive complication of
severe hypophosphatasia,18 and craniectomies
were performed in two patients.
No important concerns emerged from serum
chemical or hematologic tests or urinalyses. Serum
calcium and inorganic-phosphate levels showed
only transient minor fluctuations, and there were
Figure 3. Radiographic Findings in Patient 4.
no clinical signs of hypocalcemia from calciumA baseline radiograph shows generalized osteopenia of the chest but little
avid bones (“hungry bones”). There were no
deformity (Panel A). Consent for treatment was withdrawn during the initial
treatment-related adverse events suggestive of
intravenous infusion of ENB-0040, and the patient received no further
hypersensitivity, nor was there evidence of tachytreatment. A radiograph obtained 14 months after withdrawal shows subphylaxis. During the first 6 months, four of the
stantial skeletal deterioration (Panel B).
nine patients tested positive for anti–ENB-0040
antibodies, but titers remained relatively low
Serum parathyroid hormone was at a low- (range, 2 to 128) and did not appear to influence
normal level in 5 of 6 patients at baseline, despite clinical outcomes in the follow-up period.
dietary calcium restriction, and usually increased
during treatment, generally together with the raDISCUSSION
diographic improvements. Dietary calcium restriction was then liberalized for all infants, and for Hypophosphatasia is almost always fatal when
some, the intake was increased to a level above severe skeletal disease is obvious at birth.1,5,12
age-appropriate recommendations to control the The prognosis for patients with infantile hyporise in parathyroid hormone. The level of plasma phosphatasia is uncertain at presentation, but
PLP was elevated in all patients at baseline (Table clinical and skeletal deterioration14-17 or vitamin
1). For the 10 patients who did not receive supple- B6–responsive seizures7 indicate a lethal course.
mentation with vitamin B6, the median level was
There is no approved medical therapy for hy262 ng per milliliter (1060 nM) at baseline, 46 ng pophosphatasia.1,5 Early, unsuccessful attempts to
per milliliter (186 nM) at 24 weeks, and 23 ng per treat infantile hypophosphatasia with repeated
milliliter (93 nM) at 48 weeks (P = 0.004 and intravenous infusions of soluble alkaline phosP = 0.02, respectively). Plasma levels of inorganic phatases14,15,21 suggested that TNSALP must be
pyrophosphate were measured before and after within the skeletal matrix to mineralize cartilage
treatment in five patients; the median level de- and bone.15 Avoiding extraskeletal excesses of alcreased from 5.2 nM at baseline to 1.1 and 1.9 nM kaline phosphatase seemed important because diat weeks 24 and 48, respectively (see the Supple- minished extracellular production of inorganic
mentary Appendix).
pyrophosphate causes generalized arterial calcification of infancy.34 For life-threatening hypoADVERSE EVENTS
phosphatasia, attempts to transplant cells derived
The most common therapy-related adverse event from healthy mesenchyme to form TNSALP-replete
was a reaction at the subcutaneous-injection site, osteoblasts appeared to benefit, but not cure, two
consisting of mild, localized, transient erythema. girls with infantile hypophosphatasia.16,17 In case
There was no evidence of ectopic calcification from reports,35 teriparatide (parathyroid hormone amithe treatment, including on funduscopic examina- no acid 1-34), which stimulates the biosynthesis of
tion; nephrocalcinosis did not progress after the TNSALP in osteoblasts, appeared to be beneficial
initial 6 months of treatment and it even improved in some adults with hypophosphatasia.1
in some patients. Serious adverse events were genIn this study, we found that bone-targeted enerally consistent with severe hypophosphatasia zyme replacement with ENB-0040 was effective in
(Table 2, and the Supplementary Appendix). Three infants and young children with life-threatening
serious adverse events (one case each of respira- or severely debilitating hypophosphatasia. Of the
A
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18 Months of Age (baseline)

B

32 Months of Age
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nine patients who were treated for at least 1 year,
four had perinatal hypophosphatasia and five had
infantile hypophosphatasia. One had lost nearly
all radiographically apparent skeletal mineral during prolonged ventilation and immobilization but
still had a positive response to ENB-0040 therapy.
Serum calcium levels were generally high at diagnosis (unlike calcium levels in other forms of
rickets)1,5 and initially required dietary calcium
restriction in all patients, most of whom had
nephrocalcinosis.
Skeletal remineralization occurred during treatment, without symptomatic hypocalcemia from
calcium-avid bones, and was often accompanied
by increases in serum parathyroid hormone levels
that called for liberalization of dietary calcium
but not additional vitamin D. A positive mineral
balance throughout the skeleton was obvious on
radiography after several weeks or months of
treatment, and both membranous and endochondral bone healed in most patients, with
amelioration of nearly all complications of hypophosphatasia. Substantial radiographic improvement in skeletal abnormalities was noted at week
24 in all but one patient, with continued healing
through week 48. In the one patient who had no
radiographically visible mineral at baseline, calcification was observed after 9 months of therapy. This delay probably reflected the profound
deficit of skeletal mineral in the patient, although
sufficient hydroxyapatite was apparently present
for targeting with ENB-0040. After the start of
therapy, deciduous teeth erupted in all the patients, with only one patient having hypophosphatasia-related loss of a tooth.
Although the pathogenesis is not understood,1,5
hypophosphatasia causes weakness, seemingly
from a static myopathy.36 Improvement in ventilatory function and in fine and gross motor skills
was observed in all the patients in our study.
Muscle weakness, hyperphosphatemia, and osteomalacia that are reminiscent of hypophosphatasia occur with toxic doses of the first-generation
bisphosphonate, etidronate (a synthetic analogue
of inorganic pyrophosphate),37,38 suggesting that
an accumulation of inorganic pyrophosphate in
hypophosphatasia may have a myopathic effect. It
is possible that the improved motor function in our
patients reflected hydrolysis of inorganic pyrophosphate or some as-yet-unrecognized TNSALP
substrate.39
Although treatment with ENB-0040 markedly
n engl j med 366;10

Table 2. Serious Adverse Events during the Treatment Period.*

Event

Total serious adverse events
Infection

0–6 Months
of Treatment
(N = 11)

7–12 Months
of Treatment
(N = 10)

Events Patients

Events Patients

no.

no. (%)

no.

no. (%)

31

7 (64)

27

8 (80)

9

5 (45)

8

5 (50)

Pneumonia

3

2 (18)

2

2 (20)

Tracheitis

0

0

2

2 (20)

10

4 (36)

7

3 (30)

Respiratory distress

4

2 (18)

0

0

Respiratory failure

2

2 (18)

2

1 (10)

Nervous-system disorder

3

3 (27)

2

2 (20)

Convulsion

2

2 (18)

0

0

Increased intracranial pressure

Respiratory, thoracic, or mediastinal
disorder

1

1 (9)

2

2 (20)

General disorder or administrationsite condition

2

2 (18)

0

0

Decreased oxygen saturation

2

2 (18)

0

0

Musculoskeletal or connective-tissue
disorder — craniosynostosis

2

2 (18)

5

4 (40)

Surgical or medical procedure

0

0

2

2 (20)

* “Total serious adverse events” includes all serious adverse events, regardless
of the incidence. Multiple events could occur in a single patient. The following
serious adverse events occurred with a frequency of 10% or less during the
treatment period and are not listed in the table: gastroenteritis (salmonella),
hepatitis, H1N1 influenza, lower respiratory tract infection (viral), pneumonia
due to respiratory syncytial virus, bronchiolitis due to respiratory syncytial virus, sepsis, asthma, dyspnea, hypoxemia, obstructive airway disorder, restrictive pulmonary disease, respiratory insufficiency, chronic disease of tonsils
and adenoids, catheter-related complication, pyrexia, scoliosis, tachycardia,
craniosynostosis, collapse of lung, craniectomy, gastrostomy-tube placement,
bilateral conductive hearing loss, and renal stones. For complete data, see
Table 5 in the Supplementary Appendix.

increased serum alkaline phosphatase levels in our
patients, we found no evidence that it led to ectopic mineralization. We were concerned that
subcutaneous injections of ENB-0040 might precipitate calcium and phosphate locally, because
especially high levels of alkaline phosphatase
would be present transiently near fibrillar collagen,40 but this was not observed. Despite the
presence of calcification in the kidneys of eight
patients at baseline, no new occurrences of nephrocalcinosis were reported, and nephrocalcinosis
resolved in one patient. Perhaps this finding reflected a reduction, but not overcorrection, of
extracellular concentrations of inorganic pyrophosphate mirrored by plasma PLP levels that
approached or achieved the normal range. Cra-
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n e w e ng l a n d j o u r na l

niosynostosis and skull dysmorphology occur in
approximately 40% of infants with hypophosphatasia.18 A similar percentage of our patients had
craniosynostosis, suggesting that treatment with
ENB-0040 does not alter its natural history.
In conclusion, ENB-0040, a recombinant human TNSALP coupled to a deca-aspartate motif
for bone targeting, was administered by one intravenous infusion and then subcutaneous injections in children with perinatal or infantile hypophosphatasia. Treatment was associated with
healing of the skeletal manifestations of hypophosphatasia as well as improved respiratory and
motor function. Improvement is still being observed in the patients receiving continued ENB0040 therapy, with more than 3 years of treatment in some children. ENB-0040 appears to be a
potential enzyme-replacement therapy in patients
with life-threatening hypophosphatasia, a metabolic bone disease.
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